Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Sirukumab in Rheumatoid Arthritis (Extension of SIRROUND-D and SIRROUND-T)
jRCT2080223019Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of sirukumab in rheumatoid arthritis (RA) (2 arms), sponsored by Janssen Pharmaceutical.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080223019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223019.